TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29072043
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with Mollii® (transcutaneous electrical stimulation)
Study: 29072043
Drug: Non-active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-active treatment (placebo)
Study: 11336156
Drug: Omeprazole treatment
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole treatment
Study: 11376649
Drug: Loperamide and
Normalized name: Loperamide and simeticone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide and Acetaminophen
Study: 24588066
Drug: Adjunctive emotion
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive emotion regulation group therapy (ERGT)
Study: 19756419
Drug: Continuous 24-h
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous 24-h infusion of 100 mg/kg per day ceftazidime
Study: 15063387
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg lycopene/day (Group B)
Study: 1536016
Drug: 0.5 ml
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml (2.0 mg) of chymopapain and 2.0 ml (8.0 mg) of chymopapain
Study: 12701008
Drug: Endoscopic epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endoscopic epinephrine injection therapy for gastric body Dieulafoy lesions
Study: 1863900
Drug: Long-term immunotherapy
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term immunotherapy (more than 2 years)
Study: 1863900
Drug: Short-term immunotherapy
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term immunotherapy (less than 1 year)
Study: 1863900
Drug: Immunotherapy (general)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (general)
Study: 16732060
Drug: Intracoronary radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary radiation therapy (ICRT) with 14 Gy
Study: 1752115
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta (subcutaneous)
Study: 19501900
Drug: Active control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active control (combination of metformin and sulfonylurea, n=2227)
Study: 31771921
Drug: Higher protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher protein diet (1.2 g protein/kg BW)
Study: 26864371
Drug: Concord grape
Normalized name: Concord Grape
DrugBank: Concord grape (DB10875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concord grape juice (CGJ) - 12 ounces (355 mL) daily for 12 weeks
Study: 11231941
Drug: Naproxen, 500
Normalized name: Naproxen, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen, 500 mg twice daily for 5 days
Study: 1734637
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) (10 mg)
Study: 18394900
Drug: Hybrid therapies
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid therapies
Study: 12804345
Drug: Aerobic exercises
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercises (walking or stationary cycling) or a combination of aerobic plus spinal flexibility exercises for 1 hour 3 days a week for 3 months
Study: 10678643
Drug: Mefar dosimeter
Normalized name: sulfacetamide sodium Medicated Liquid Soap [Mexar]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefar dosimeter protocol (PD20 value of <=0.5 mg)
Study: 11380067
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg dose of metronidazole
Study: 7767
Drug: Formula 4
Normalized name: Formula 405 Soap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula 4 (3.0 gm of protein per 100 ml, 18:82)
Study: 29471855
Drug: 16 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 sessions of eye movement desensitization and reprocessing (EMDR) therapy preceded by a stabilization phase (8 sessions of Skills Training in Affect and Interpersonal Regulation (STAIR))
Study: 23731911
Drug: Off therapy
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Off therapy
Study: 2651248
Drug: Dosulepin (Idom)
Normalized name: dosulepin
DrugBank: Dosulepin (DB09167)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosulepin (Idom) 75 mg daily in the evening
Study: 19146991
Drug: Concurrent marginal
Normalized name: Culex marginalis
DrugBank: Culex pipiens (DB14165)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent marginal maximum likelihood (MML)
Study: 16710252
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of perindopril (2 mg) and indapamide (0.625 mg)
Study: 16441782
Drug: Subgingival plaque
Normalized name: Plaquenil
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subgingival plaque samples from peri-implant pockets
Study: 29412521
Drug: Endobronchially administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endobronchially administered adipose-derived stem cells (ADSCs)
Study: 24803644
Drug: VR group
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VR group (n=11) received nine 30 minutes upper extremity VR therapy in standing plus conventional therapy
Study: 26868210
Drug: Bronchodilator use
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilator use
Study: 20968113
Drug: High polyphenol
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High polyphenol chocolate (45 g daily for 8 weeks)
Study: 20968113
Drug: Low polyphenol
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low polyphenol chocolate (45 g daily for 8 weeks)
Study: 18552464
Drug: Interferon-beta therapy
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-beta therapy (6 MU daily for 6 or 8 weeks)
Study: 7094972
Drug: Neomycin sulphate
Normalized name: Neomycin sulphate
DrugBank: Neomycin (DB00994)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neomycin sulphate 1.5 g/d and d‐thyroxine 6 mg/d for 8 weeks
Study: 23799935
Drug: Omalizumab +
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab + Specific Immunotherapy (SIT)
Study: 23799935
Drug: Specific Immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific Immunotherapy (SIT) + Placebo
Study: 31256014
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (10 sessions, two times per week)
Study: 31303281
Drug: Lusutrombopag (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lusutrombopag (0.75 mg) in fed state
Study: 28355708
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of Ginkgo biloba (Ginaton) 70 mg once a day for 2 weeks
Study: 10965516
Drug: Yogurt treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yogurt treatment (2 cups, 454 g/day) for three months
Study: 31536806
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (CEE 0.625 mg/day) plus medroxyprogesterone acetate (MPA 2.5 mg/day)
Study: 19317814
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg of Ca(2+) orally, daily for 8 weeks
Study: 10831926
Drug: Graded hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded hormone replacement therapy (HRT) doses
Study: 24178236
Drug: Mirabegron OCAS
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron OCAS 100-200 mg once daily for 7 days
Study: 19209184
Drug: Hydroxypropylmethylcellulose (HPMC)
DrugBank: Hypromellose (DB11075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxypropylmethylcellulose (HPMC) 2.5 g twice daily for 4 weeks
Study: 31112652
Drug: Phonomotor treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phonomotor treatment
Study: 19458163
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of methotrexate (MTX) and sulfasalazine (SSZ) in patients who previously failed SSZ
Study: 18086463
Drug: Open-label PUFA
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label PUFA administration
Study: 20967993
Drug: solifenacin (vesikar)
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: solifenacin (vesikar) 5 mg/day
Study: 12821733
Drug: Matching IV
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching IV and oral placebos
Study: 23015750
Drug: Group Cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Cognitive Behaviour Therapy (CBT) - 6 sessions
Study: 20414695
Drug: Hot-pack +
Normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hot-pack + laser therapy (acute LDH, n = 20)
Study: 20414695
Drug: Hot-pack +
Normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hot-pack + laser therapy (chronic LDH, n = 20)
Study: 29635419
Drug: BCG vaccine
Normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccine in other children (not born by cesarean section)
Study: 29635419
Drug: BCG vaccine
Normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccine in premature children
Study: 29635419
Drug: BCG vaccine
Normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccine in children born at term
Study: 17587516
Drug: tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tibolone 2.5 mg/day
Study: 25049330
Drug: Sequential everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sequential everolimus then sunitinib
Study: 7590572
Drug: Granular formulation
Normalized name: Saxifraga granulata whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granular formulation of sucralfate (2.0 g twice daily)
Study: 30643079
Drug: Dabigatran 110
Normalized name: dabigatran 110 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 110 mg dual therapy
Study: 23224788
Drug: 125 mg
Normalized name: niacin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg aprepitant
Study: 21109344
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg
Study: 29667763
Drug: Dutasteride 0.5
Normalized name: dutasteride 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.5 mg
Study: 8633187
Drug: felodipine 5
Normalized name: felodipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: felodipine 5 mg
Study: 17264338
Drug: Intravenous fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fluorouracil (FU) plus leucovorin (LV)
Study: 7995059
Drug: Single pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single pulse therapy (500 mg of methylprednisolone)
Study: 7995059
Drug: Second pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second pulse therapy at 24 hours (500 mg of methylprednisolone)
Study: 7995059
Drug: Second pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second pulse therapy at 48 hours (500 mg of methylprednisolone)
Study: 17229251
Drug: Volunteer-mediated intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Volunteer-mediated intervention (daily orientation, therapeutic activities, feeding and hydration assistance, vision and hearing protocols)
Study: 12799847
Drug: Tramadol 50
Normalized name: traMADol 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 50 mg
Study: 31974099
Drug: Rapid insulin-alone
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rapid insulin-alone artificial pancreas
Study: 21385145
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg once daily after THR
Study: 17446716
Drug: Topical administration
Normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical administration of lutein and zeaxanthin
Study: 8299431
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (d‐alpha‐tocopherol; 900 mg/day)
Study: 16163899
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg Ticlid tablets (reference formulation)
Study: 14585916
Drug: COX-2-specific inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: COX-2-specific inhibitors (celecoxib or valdecoxib)
Study: 1763292
Drug: Prednisolone 25
Normalized name: prednisolone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 25 mg/100 ml
Study: 29264713
Drug: Liraglutide 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 0.9 mg
Study: 21980798
Drug: Specific sublingual
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific sublingual immunotherapy (SLITOne, ALK) for two consecutive pollen seasons
Study: 28459989
Drug: Experimental intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental intervention (EX): Usual care (nutrition and PA education materials) plus 2‐month supervised weekly physical activity and behaviour change sessions.
Study: 7639342
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg d-alpha-tocopherol per day for 3 weeks
Study: 7639342
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg d-alpha-tocopherol per day for 3 weeks
Study: 14587651
Drug: Nifedipine SR
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine SR (20 mg/day)
Study: 6761928
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 2 mg pessaries administered four hourly
Study: 25085073
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus GG (L.GG)
Study: 19287552
Drug: Adjunctive aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjunctive aripiprazole (2-20 mg/day)
Study: 12725663
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen (50 microg estradiol patch weekly)
Study: 17664149
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1 g intravenous infusion)
Study: 16225161
Drug: MR carbonyl
Normalized name: Iron, Carbonyl
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MR carbonyl iron (45 mg)
Study: 26781763
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (1000 IU) and Evening Primrose Oil (1000 mg)
Study: 18616780
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%)
Study: 9829447
Drug: Hydroquinone 4%
Normalized name: HYDROQUINONE 4% CREAM
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroquinone 4% cream
Study: 6382936
Drug: meglumine iothalamate
Normalized name: meglumine ioxithalamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: meglumine iothalamate 280 mg I/ml
Study: 6377118
Drug: iohexol 300
Normalized name: IOHEXOL 300MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: iohexol 300 mg I/ml
Study: 22550196
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil capsules (four 1-g capsules/d)
Study: 18958837
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy in critically ill non-ACS patients
Study: 20819892
Drug: MF59-adjuvanted H5N1
Normalized name: Influenza A monovalent (H5N1), ADJUVANTED-2013
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted H5N1 vaccine (7.5 μg/dose)
Study: 10050562
Drug: Glucosamine HCl
Normalized name: glucosamine HCl
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine HCl (1,500 mg/day), chondroitin sulfate (1,200 mg/day), and manganese ascorbate (228 mg/day)
Study: 19349517
Drug: Nikkomycin Z
Normalized name: Nikkomycin Z
DrugBank: Nikkomycin Z (DB12939)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nikkomycin Z 1,000 mg
Study: 19349517
Drug: Nikkomycin Z
Normalized name: Nikkomycin Z
DrugBank: Nikkomycin Z (DB12939)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nikkomycin Z 1,500 mg to 2,000 mg
Study: 8692147
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (10 mg) given via portal system for intestinal type
Study: 8692147
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (10 mg) given in peritoneal cavity for diffuse type
Study: 8203796
Drug: Flunisolide nasal
Normalized name: flunisolide nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunisolide nasal spray
Study: 9328492
Drug: Intensive psychosocial
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive psychosocial treatment
Study: 8146409
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg salbutamol CR twice daily
Study: 7020820
Drug: all 3
Normalized name: Small 33G Lancet
Approvals — FDA: no, EMA: no, PMDA: no
Description: all 3 antibiotics
Study: 1300782
Drug: Adjuvant hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant hormone therapy in ER+PR+ tumor patients
Study: 8811478
Drug: Complex therapy
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex therapy
Study: 9894374
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg (increased to 10 mg if necessary)
Study: 12544672
Drug: Transdermal progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal progesterone cream (32 mg daily)
Study: 10430149
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered sonographic contrast agent (200, 400, 600, 800, or 1000 ml)
Study: 18044102
Drug: Racemic albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic albuterol
Study: 28052570
Drug: Youth Fit
Normalized name: influenza A virus A/South Australia/34/2019 (H3N2) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Youth Fit 4 Life (YF4L) treatment group
Study: 11253857
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rate control and anticoagulation with cardioversion if AF persists
Study: 26704612
Drug: Tetravalent dengue
Normalized name: dengue virus live antigen, CYD serotype 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent dengue vaccine candidate (TDV)
Study: 26646759
Drug: Afatinib plus
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib plus paclitaxel (40 mg/day; 80 mg/m²/week)
Study: 11315234
Drug: Tiludronate 200
Normalized name: tiludronate 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiludronate 200 mg/day
Study: 7747617
Drug: Tiludronate 400
Normalized name: tiludronate
DrugBank: Tiludronic acid (DB01133)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiludronate 400 mg/day
Study: 2282920
Drug: Felodipine 5
Normalized name: felodipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 5 mg twice daily for 2 weeks
Study: 11103054
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa low-dose (20,000 U)
Study: 26575158
Drug: End of
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: End of therapy HADS-D
Study: 20370840
Drug: Inhaled insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled insulin therapy
Study: 8546737
Drug: 1 mg/day
Normalized name: Lyllana 0.1 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/day oral bovine type II collagen (n = 30)